InnoCore Pharmaceuticals

InnoCore Pharmaceuticals

Private
GroningenHealthcare & Life Scienceshttps://innocorepharma.com/

Last Round

Grant

Nov 10, 2025

Total Funding Raised

$1.73M

Momentum Score

25 /100

Company Overview

InnoCore Pharmaceuticals is a drug delivery company that develops long-acting injectable and biodegradable drug delivery formulations for pharmaceutical and biotech partners.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Advanced Materials, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

long-acting injectabledrug delivery platformsustained releaseformulation developmentCDMOLAIpeptide deliverybiologic drug deliverybiodegradable polymerdepot formulationCROmicrospheresbiodegradable implantinjectable gelco-development partner

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InnoCore Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

InnoCore Pharmaceuticals Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantNov 10, 2025
GrantJan 1, 2021
GrantJun 1, 2020
GrantJan 11, 2019

Key People

Founding team and executive leadership

Bart-Jan Korteling

Chief Operating Officer

Executive Team

InnoCore Pharmaceuticals Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2025

    Received funding from the EU Just Transition Fund.

  • May 1, 2025

    Monthly visitors grew 617% MoM, reaching 2K.

InnoCore Pharmaceuticals Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InnoCore Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InnoCore Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersGroningen
Employee Range50
Year Founded2003
Last FundingNov 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.